Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
In this episode of the Drug Solutions podcast, Jill Murphy, Editor, talks to Michael Schrader, CEO and co-founder of Vaxess, about the fast pace in production in the pharmaceutical industry, mRNA versus DNA for new vaccines, and the new types of technology used for vaccine administration.
Michael Schrader is the CEO and co-founder of Vaxess, a life sciences company developing the MIMIX™ sustained release vaccine patch technology. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness. Michael has spent his career transforming complex technologies into transformational products. Prior to Vaxess, he spent time at Google and Honda where he helped bring a range of products to market and earned more than fifteen patents. Michael received his B.S. in Mechanical Engineering from Purdue University and his M.B.A. from Harvard.
Pharmaceutical Technology presents the Drug Solutions podcast, where the editors will chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products.